Performance of vitek 2 for antimicrobial susceptibility testing of acinetobacter baumannii, pseudomonas aeruginosa, and stenotrophomonas maltophilia with vitek 2 (2009 FDA) and CLSI M100S 26th edition breakpoints

Journal of Clinical Microbiology

Volumn 55, Issue 2, 2017, Pages 450-456

  Bobenchik, April M ^a,c   Deak, Eszter ^a,d   Hindler, Janet A ^b   Charlton, Carmen L ^a,e   Humphries, Romney M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Lifespan   (United States)

^d KAISER PERMANENTE   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acinetobacter baumannii; Antimicrobial susceptibility testing; Breakpoints; Broth microdilution; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Vitek 2

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 85012026187     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01859-16     Document Type: Article

References (17)

1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Stuelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
2. Weiner LM, Fridkin SK, Aponte-Torres Z, Avery L, Coffin N, Dudeck MA, Edwards JR, Jernigan JA, Konnor R, Soe MM, Peterson K, McDonald LC. 2016. Vital signs: Preventing antibiotic-resistant infections in hospitals-United States, 2014. MMWR Morb Mortal Wkly Rep 65: 235-241. https://doi.org/10.15585/mmwr.mm6509e1.
3. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. 2010. Attributable hospital cost and length of stay associated with health careassociated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob Agents Chemother 54:109-115. https://doi.org/10.1128/AAC.01041-09.
4. Markelz AE, Mende K, Murray CK, Yu X, Zera WC, Hospenthal DR, Beckius ML, Calvano T, Akers KS. 2011. Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii-calcoaceticus complex. Antimicrob Agents Chemother 55: 4707-4711. https://doi.org/10.1128/AAC.00112-11.
5. Juretschko S, Labombardi VJ, Lerner SA, Schreckenberger PC, Pseudomonas AST Study Group. 2007. Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2). J Clin Microbiol 45:1339-1342. https://doi.org/10.1128/JCM.01716-06.
6. Kulah C, Aktas E, Comert F, Ozlu N, Akyar I, Ankarali H. 2009. Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan WalkAway, Vitek 2); high error rates with Microscan WalkAway. BMC Infect Dis 9:30. https://doi.org/10.1186/1471-2334-9-30.
7. Mazzariol A, Aldegheri M, Ligozzi M, Lo Cascio G, Koncan R, Fontana R. 2008. Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of betalactam resistance. J Clin Microbiol 46:2095-2098. https://doi.org/10.1128/JCM.02216-07.
8. Bobenchik AM, Deak E, Hindler JA, Charlton CL, Humphries RM. 2015. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints. J Clin Microbiol 53:816-823. https://doi.org/10.1128/JCM.02697-14.
9. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26 ed. CLSI supplement M100S. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Torres E, Villanueva R, Bou G. 2009. Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa. J Med Microbiol 58:625-629. https://doi.org/10.1099/jmm.0.005587-0.
12. Otto-Karg I, Jandl S, Müller T, Stirzel B, Frosch M, Hebestreit H, Abele- Horn M. 2009. Validation of Vitek 2 nonfermenting Gram-negative cards and Vitek 2 version 4.02 software for identification and antimicrobial susceptibility testing of nonfermenting gram-negative rods from patients with cystic fibrosis. J Clin Microbiol 47:3283-3288. https://doi.org/10.1128/JCM.00505-09.
13. bioMérieux. 2012. VITEK 2 AST-GN69 product information. REV 072012. bioMérieux, Inc., Durham, NC.
14. Humphries RM, Hindler JA. 2016. Emerging resistance, new antimicrobial agents. . .but no tests! The challenge of antimicrobial susceptibility testing in the current US regulatory landscape. Cin Infect Dis 63:83-88. https://doi.org/10.1093/cid/ciw201.
15. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
16. bioMérieux. 2012. VITEK 2 AST-XN06 product information. REV 042012. bioMérieux, Inc., Durham, NC.
17. Clark RB, Lewinski MA, Loeffelholz MJ, Tibbetts RJ. 2009. Cumitech 31A, verification and validation of procedures in the clinical microbiology laboratory. Sharp SE (ed). ASM Press, Washington, DC.